Letter on 'European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis'

Mark, P. , Dekkers, I., Blankestijn, P., Leiner, T. and Roditi, G. (2018) Letter on 'European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis'. Journal of the European Academy of Dermatology and Venereology, 32(2), e84-e85. (doi: 10.1111/jdv.14774) (PMID:29283443)

[img]
Preview
Text
154356.pdf - Accepted Version

226kB

Abstract

We read with interest the guidelines recently published on sclerosing diseases of the skin (Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis)[1, 2]. However, we are concerned that the guideline recommendations proposed for prevention of nephrogenic systemic fibrosis (NSF) are potentially dangerous. Although we recognise the challenges in constructing comprehensive guidelines, we are concerned that this may be because the guidelines have not involved a multidisciplinary team.

Item Type:Articles (Letter)
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Roditi, Dr Giles and Mark, Professor Patrick
Authors: Mark, P., Dekkers, I., Blankestijn, P., Leiner, T., and Roditi, G.
Subjects:R Medicine > RC Internal medicine
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Journal of the European Academy of Dermatology and Venereology
Publisher:Wiley
ISSN:0926-9959
ISSN (Online):1468-3083
Published Online:28 December 2017
Copyright Holders:Copyright © 2017 European Academy of Dermatology and Venereology
First Published:First published in Journal of the European Academy of Dermatology and Venereology 32(2): e84-e85
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record